Valine

Valine

SCHEMBL598198

CC(C)[C@H](N)C(=O)O.Clc1ccnc(Cl)n1

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.47
KDM4C Q9H3R0 1/20 0.35
MAPT P10636 1/20 0.35
PANK3 Q9H999 1/20 0.33
MEN1 O00255 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
FFAR1 O14842 1/20 0.32
AAK1 Q2M2I8 2/20 0.32
TRPV1 Q8NER1 1/20 0.32
CIT O14578 1/20 0.32
ACHE P22303 1/20 0.31
NR1I2 O75469 1/20 0.31
PTGS1 P23219 1/20 0.31
ADRA1A P35348 1/20 0.31
LMNA P02545 1/20 0.31
BLM P54132 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Valine SCHEMBL1759337 0.82 SLC7A5 (0.56) SLC7A5KDM4CMEN1CYP2D6CYP2C9
SCHEMBL11481575 0.77 NAPRT (0.41) KDM4CMAPTFFAR1TRPV1LMNA
Valine SCHEMBL1842424 0.76 TDP1 (0.52) SLC7A5LMNATDP1XIAPBIRC2
Valine SCHEMBL3396293 0.74 SLC7A5 (0.46) SLC7A5
Valine SCHEMBL9998032 0.74 SLC7A5 (0.42) SLC7A5ALDH1A1SMN1; SMN2
Valine SCHEMBL14125780 0.74 SLC7A5 (0.42) SLC7A5LMNA
Valine SCHEMBL7070552 0.73 SLC7A5 (0.54) SLC7A5KDM4CMEN1CYP2D6CYP2C9
SCHEMBL63023 0.73
SCHEMBL29483856 0.73
Nitrapyrin SCHEMBL21777792 0.73 CYP3A4 (0.59) SLC7A5MAPTMEN1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114875-B2 Substituted N-heterocyclic compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2012-02-14 US disclosed
US-8008488-B2 Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands ABBOTT GMBH & CO. KG (DE) 2011-08-30 US disclosed
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands ABBOTT GMBH & CO. KG (DE) 2009-02-26 US disclosed
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ABBOT GMBH & CO. KG (DE) 2006-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235004-A1 Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands ADRB3, DRD3, OPRL1 SLC7A5 476/4885KDM4C 3434/4885MAPT 1307/4885
US-20090054449-A1 Substituted N-heterocyclic Compounds and Their Use as Dopamine D3 Receptor Ligands SLC6A3, DRD3, HTR3A SLC7A5 342/4885KDM4C 4588/4885MAPT 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.